ch3biosystems2024年價格表
CH3 BioSystems是一家生物技術公司，基于一種全新的受專li保護的化學技術，旨在識別和商業(yè)化候選藥物和診斷藥物。
我們制造促進生物醫(yī)學研究的新型分子工具。我們的目標是更好地了解影響全球數(shù)百萬人的癌癥、自身免疫疾病、神經(jīng)發(fā)育疾病、病毒性疾病和心血管疾病。
我們的長期愿景是促進基于蛋白質甲基化生物學新興領域的診斷和藥物產(chǎn)品的開發(fā)。
特別告知：為保證產(chǎn)品質量與良好性能，所以在購買相應產(chǎn)品的同時我司會收取一定量的運輸費用?。?！本次報價有效時間為2024年1月5日---2024年12月14日。
| 貨號 | 品名 | 規(guī)格 | 價格 | 品牌 | 貨期 | 價格來源 |
| 92C001 | Human Embryonic Kidney (HEK) - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 800001 | Methylarginine-specific antibody | 20mg | 4554.46 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 800002 | Methylarginine-specific antibody | 100mg | 8653.47 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 810001 | Control antibody reagent | 20mg | 3188.12 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 810002 | Control antibody reagent | 100mg | 5009.91 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150001 | IgY Anti-2B | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150002 | IgY Anti-DEx3 | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150003 | IgY Anti-survivin | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 150004 | IgY Anti-survivin 3B | 100ml | 6376.24 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 820001 | Type I Arginine methyltransferase | 200ml | 26415.86 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 820002 | Type III Arginine methyltransferase | 200ml | 42811.92 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 830001 | Methylation substrate | 10mg | 3370.30 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 830002 | Methylation substrate | 25mg | 5592.88 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 890001 | Methyl donor | 500ml | 2732.68 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 91A001 | PC12 pheochromocytoma | Vial | 7196.05 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91C001 | PC12 pheochromocytoma - Corporate | Vial | 21432.75 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91A002 | PC12-C41 variant PC12 cell line | Vial | 7196.05 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91C002 | PC12-C41 variant PC12 cell line - Corporate | Vial | 21432.75 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91A003 | PC12Mn variant PC12 cell line | Vial | 7196.05 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 91C003 | PC12Mn variant PC12 cell line - Corporate | Vial | 21432.75 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 92A001 | Human Embryonic Kidney (HEK) | Vial | 5920.80 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 92AP01 | Human Embryonic Kidney (HEK) -Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 93A001 | HepG2 hepatocellular carcinoma | Vial | 5920.80 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 93AP01 | HepG2 hepatocellular carcinoma - Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 93C001 | HepG2 hepatocellular carcinoma - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A001 | E0771 breast adenocarcinoma | Vial | 8198.03 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP01 | E0771 breast adenocarcinoma - Premium | Vial | 18217.84 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C001 | E0771 breast adenocarcinoma - Corporate | Vial | 139312.88 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A002 | LNCaP Human prostate cancer | Vial | 6376.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP02 | LNCaP Human prostate cancer - Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C002 | LNCaP Human prostate cancer - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A003 | HeLa Human cervical cancer | Vial | 6376.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP03 | HeLa Human cervical cancer - Premium | Vial | 13663.38 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C003 | HeLa Human cervical cancer - Corporate | Vial | 18217.84 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94A012 | PC-3 | Vial | 6376.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94AP12 | PC-3 - Premium | Vial | 9108.92 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 94C012 | PC-3 - Corporate | Vial | 16074.56 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 99A001 | Rat tail collagen | 1ml | 4536.24 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 99A002 | Cell Sep | ea | 3279.21 | ch3biosystems | 3-6月 | 上海起發(fā) |
| 870001 | Inhibitor A | 100ml | 1457.43 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 870002 | Inhibitor A | 500ml | 3279.21 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 880001 | Inhibitor B | 1ml | 1457.43 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 880002 | Inhibitor B | 5ml | 3279.21 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 840001 | Low ionic strength buffer | 100ml | 261.38 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 860001 | High capacity buffer | 100ml | 261.38 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110000 | pLuc Reporter Vector | ea | 2700.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110001 | LucNeo | ea | 3600.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110002 | Hsp-6270 | ea | 5980.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110003 | Hsp-3569neo | ea | 5980.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
| 110004 | Hsp-3338neo | ea | 5980.00 | ch3biosystems | 4-6周 | 上海起發(fā) |
（*此為部分產(chǎn)品價格完整價格請下載文件）
關鍵詞：ch3biosystems、甲基精氨酸特異性抗體、甲基蛋白、ch3biosystems 92C001、ch3biosystems 150001
